CMAB017

Phase 1Small molecule

TTaizhou Mabtech Pharmaceutical Co.,Ltd

CMAB017 is one of 5 small molecule programs targeting Solid Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid MalignanciesRecruiting

Solid MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Solid Malignancies

#DrugCompanyPhaseTrials

Dostarlimab

Incyte

Phase 2

1 2

Jakafi

Incyte

Phase 2

1 3

Imfinzi

AstraZeneca

Phase 1

1 4

Imjudo

AstraZeneca

Phase 1

1 5

CMAB017

TTaizhou Mabtech Pharmaceutical Co.,Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Solid Malignancies

NCT06933069

Clinical

Trials by Indication[1]

Solid Malignancies1 trial

A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Anti-tumor Activity of CMAB017 in Advanced Malignant Solid Tumors

Recruiting·TTaizhou Mabtech Pharmaceutical Co.,Ltd·Phase 1·NCT06933069·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CMAB017. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CMAB017 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CMAB017. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taizhou Mabtech Pharmaceutical Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTaizhou Mabtech Pharmaceutical Co.,Ltd

CMAB017

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Solid Malignancies1 trial

References

Drug Info

Quick Facts

Related News